Amarin | AMRN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12